{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:05:16Z","timestamp":1773140716235,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-022-00891-4","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T06:02:47Z","timestamp":1663567367000},"page":"655-666","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Coagulopathy during COVID-19 infection: a brief review"],"prefix":"10.1007","volume":"23","author":[{"given":"Robin M.","family":"Cunningham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-9455","authenticated-orcid":false,"given":"Kyle L.","family":"Johnson Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-0321","authenticated-orcid":false,"given":"Jacen S.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565\u201374.","journal-title":"Lancet"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"e2104241118","DOI":"10.1073\/pnas.2104241118","volume":"118","author":"ND Rochman","year":"2021","unstructured":"Rochman ND, Wolf YI, Faure G, Mutz P, Zhang F, Koonin EV. Ongoing global and regional adaptive evolution of SARS-CoV-2. Proc Nat Acad Sci USA. 2021;118:e2104241118.","journal-title":"Proc Nat Acad Sci USA"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10311-020-01151-1","volume":"19","author":"E Sallard","year":"2021","unstructured":"Sallard E, Halloy J, Casane D, Decroly E, van Helden J. Tracing the origins of SARS-COV-2 in coronavirus phylogenies: a review. Environ Chem Lett. 2021;19:1\u201317.","journal-title":"Environ Chem Lett"},{"key":"891_CR4","unstructured":"World Health Organization (2022) WHO health emergency dashboard [Internet]. Geneva, Switzerland: World Health Organization. Available from: https:\/\/covid19.who.int\/"},{"key":"891_CR5","unstructured":"World Health Organization (2021) Strategic advisory group of experts on immunization (SAGE) [Internet]. Geneva, Switzerland: World Health Organization. Available from: https:\/\/www.who.int\/groups\/strategic-advisory-group-of-experts-on-immunization\/covid-19-materials"},{"key":"891_CR6","unstructured":"Worldometer (2022) Worldometer World Population [Internet]. 2022. Available from: https:\/\/www.worldometers.info\/population\/"},{"key":"891_CR7","unstructured":"Strandberg K (2017) The clinical use of a D-dimer assay [Internet]. Br\u00f8nsh\u00f8j, Denmark: Acute Care Testing. Available from: https:\/\/acutecaretesting.org\/-\/media\/acutecaretesting\/files\/pdf\/the-clinical-use-of-a-ddimer-assay.pdf"},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.120.048925","volume":"142","author":"P Masi","year":"2020","unstructured":"Masi P, H\u00e9kimian G, Lejeune M, Chommeloux J, Desnos C, Pineton De Chambrun M, et al. Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: insights from a prospective, single-center cohort study. Circulation. 2020;142:611\u20134.","journal-title":"Circulation"},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","volume":"136","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136:489\u2013500. https:\/\/doi.org\/10.1182\/blood.2020006520.","journal-title":"Blood"},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2147\/RMHP.S268238","volume":"13","author":"X Long","year":"2020","unstructured":"Long X, Zhang Z, Zou W, Ling J, Li D, Jing L, et al. Coagulopathy of patients with COVID-19 is associated with infectious and inflammatory markers. Risk Manage Healthcare policy. 2020;13:1965\u201375.","journal-title":"Risk Manage Healthcare policy"},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells8050471","volume":"8","author":"RG Akwii","year":"2019","unstructured":"Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of Angiopoietin-2 in Vascular physiology and pathophysiology. Cells. 2019;8:471.","journal-title":"Cells"},{"issue":"Suppl 1","key":"891_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ijlh.13547","volume":"43","author":"KMJ Devreese","year":"2021","unstructured":"Devreese KMJ. COVID-19-related laboratory coagulation findings. Int J Lab Hematol. 2021;43(Suppl 1):36\u201342.","journal-title":"Int J Lab Hematol"},{"key":"891_CR13","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1111\/jth.14994","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020;18:2191\u2013201.","journal-title":"J Thromb Haemost"},{"key":"891_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12185-020-03029-y.pdf","volume":"113","author":"H Asakura","year":"2021","unstructured":"Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113:45\u201357. https:\/\/doi.org\/10.1007\/s12185-020-03029-y.pdf.","journal-title":"Int J Hematol"},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11239-020-02134-3.pdf","volume":"50","author":"RC Becker","year":"2020","unstructured":"Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54\u201367. https:\/\/doi.org\/10.1007\/s11239-020-02134-3.pdf.","journal-title":"J Thromb Thrombolysis"},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1055\/s-0040-1713637.pdf","volume":"120","author":"E Weiss","year":"2020","unstructured":"Weiss E, Roux O, Moyer J-D, Paugam-Burtz C, Boudaoud L, Ajzenberg N, et al. Fibrinolysis resistance: a potential mechanism underlying COVID-19 coagulopathy. Thromb Haemost. 2020;120:1343\u20135. https:\/\/doi.org\/10.1055\/s-0040-1713637.pdf.","journal-title":"Thromb Haemost"},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/anae.15141","volume":"75","author":"J Thachil","year":"2020","unstructured":"Thachil J, Agarwal S. Understanding the COVID-19 coagulopathy spectrum. Anaesthesia. 2020;75:1432\u20136. https:\/\/doi.org\/10.1111\/anae.15141.","journal-title":"Anaesthesia"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.120.048488","volume":"142","author":"L Nicolai","year":"2020","unstructured":"Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, et al. Immunothrombotic dysregulation in COVID-19 Pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142:1176\u201389.","journal-title":"Circulation."},{"key":"891_CR19","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.06.182972v1.full.pdf","author":"ES FitzGerald","year":"2020","unstructured":"FitzGerald ES, Jamieson AM. Unique transcriptional changes in coagulation cascade genes in SARS-CoV-2-infected lung epithelial cells: a potential factor in COVID-19 coagulopathies. BioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.06.182972v1.full.pdf.","journal-title":"BioRxiv"},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00011-020-01401-6.pdf","volume":"69","author":"T Iba","year":"2020","unstructured":"Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69:1181\u20139. https:\/\/doi.org\/10.1007\/s00011-020-01401-6.pdf.","journal-title":"Inflamm Res"},{"key":"891_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.thromres.2020.09.018","volume":"196","author":"AL Parks","year":"2020","unstructured":"Parks AL, Auerbach AD, Schnipper JL, Anstey JE, Sterken DG, Hecht TEH, et al. COVID-19 coagulopathy and thrombosis: analysis of hospital protocols in response to the rapidly evolving pandemic. Thromb Res. 2020;196:355\u20138.","journal-title":"Thromb Res"},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1515\/cclm-2020-0188\/html","volume":"58","author":"H Han","year":"2020","unstructured":"Han H, Yang L, Liu R, Liu F, Wu K-L, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58:1116\u201320. https:\/\/doi.org\/10.1515\/cclm-2020-0188\/html.","journal-title":"Clin Chem Lab Med"},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/path.1440","volume":"200","author":"Y Ding","year":"2003","unstructured":"Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200:282\u20139.","journal-title":"J Pathol"},{"key":"891_CR24","doi-asserted-by":"publisher","first-page":"10083","DOI":"10.1128\/JVI.79.15.10083-10087.2005","volume":"79","author":"Y-J Tan","year":"2005","unstructured":"Tan Y-J, Tham P-Y, Chan DZL, Chou C-F, Shen S, Fielding BC, et al. The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells. J Virol. 2005;79:10083\u20137.","journal-title":"J Virol"},{"key":"891_CR25","doi-asserted-by":"publisher","first-page":"107602962094329","DOI":"10.1177\/1076029620943293","volume":"26","author":"A Jayarangaiah","year":"2020","unstructured":"Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clin Appl Thromb Hemost. 2020;26:1076029620943293. https:\/\/doi.org\/10.1177\/1076029620943293.","journal-title":"Clin Appl Thromb Hemost"},{"key":"891_CR26","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2213-2600(20)30600-7","volume":"9","author":"LYC Chen","year":"2021","unstructured":"Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Assessing the importance of interleukin-6 in COVID-19. Lancet Respiratory Med. 2021;9:e13.","journal-title":"Lancet Respiratory Med"},{"key":"891_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000512007","volume":"88","author":"GD Wool","year":"2021","unstructured":"Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88:15\u201327.","journal-title":"Pathobiology"},{"key":"891_CR28","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","volume":"48","author":"T Iba","year":"2020","unstructured":"Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48:1358\u201364.","journal-title":"Crit Care Med"},{"key":"891_CR29","volume-title":"International prospective registry for the diagnosis and management of disseminated intravascular coagulation in the ICU","author":"International Society on Thrombosis and Haemostasis (ISTH)","year":"2021","unstructured":"International Society on Thrombosis and Haemostasis (ISTH). International prospective registry for the diagnosis and management of disseminated intravascular coagulation in the ICU. Carrboro, NC: International Society on Thrombosis and Haemostasis; 2021."},{"key":"891_CR30","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","volume":"7","author":"M Levi","year":"2020","unstructured":"Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438-40.","journal-title":"Lancet Haematol."},{"key":"891_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","volume":"13","author":"B Engelmann","year":"2013","unstructured":"Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34\u201345.","journal-title":"Nat Rev Immunol."},{"key":"891_CR32","doi-asserted-by":"publisher","first-page":"e0135738","DOI":"10.1371\/journal.pone.0135738","volume":"10","author":"H Zhi","year":"2015","unstructured":"Zhi H, Dai J, Liu J, Zhu J, Newman DK, Gao C, et al. Platelet activation and thrombus formation over IgG immune complexes requires integrin \u03b1IIb\u03b23 and Lyn Kinase. PLoS One. 2015;10:e0135738. https:\/\/doi.org\/10.1371\/journal.pone.0135738.","journal-title":"PLoS One."},{"key":"891_CR33","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.smim.2016.10.013","volume":"28","author":"S-J Kim","year":"2016","unstructured":"Kim S-J, Jenne CN. Role of platelets in neutrophil extracellular trap (NET) production and tissue injury. Semin Immunol. 2016;28:546\u201354.","journal-title":"Semin Immunol."},{"key":"891_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fcvm.2019.00085","volume":"6","author":"AZ Zucoloto","year":"2019","unstructured":"Zucoloto AZ, Jenne CN. Platelet-neutrophil interplay: insights into neutrophil extracellular trap (NET)-driven coagulation in infection. Front Cardiovasc Med. 2019;6:85.","journal-title":"Front Cardiovasc Med."},{"key":"891_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1358863X20932640","volume":"25","author":"ME Colling","year":"2020","unstructured":"Colling ME, Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020;25:471\u20138. https:\/\/doi.org\/10.1177\/1358863X20932640.","journal-title":"Vasc Med."},{"key":"891_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1164\/rccm.1936P9","volume":"193","author":"A White","year":"2016","unstructured":"White A, Fan E. What is ECMO? Am J Respir Crit Care Med. 2016;193:9\u201310. https:\/\/doi.org\/10.1164\/rccm.1936P9.","journal-title":"Am J Respir Crit Care Med."},{"key":"891_CR37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/MAT.0000000000001208","volume":"66","author":"H Yusuff","year":"2020","unstructured":"Yusuff H, Zochios V, Brodie D. Thrombosis and coagulopathy in COVID-19 patients requiring extracorporeal membrane oxygenation. Asaio J. 2020;66:844\u20136.","journal-title":"Asaio J."},{"key":"891_CR38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s13312-020-1962-z","volume":"57","author":"S Bhattacharjee","year":"2020","unstructured":"Bhattacharjee S, Banerjee M, Pal R. COVID-19 associated hemophagocytic lymphohistiocytosis and coagulopathy: targeting the duumvirate. Ind Pediatr. 2020;57:827\u201333.","journal-title":"Ind Pediatr."},{"key":"891_CR39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1515\/cclm-2020-0502","volume":"58","author":"J Harenberg","year":"2020","unstructured":"Harenberg J, Favaloro E. COVID-19: progression of disease and intravascular coagulation \u2013 present status and future perspectives. Clin Chem Lab Med (CCLM). 2020;58:1029\u201336. https:\/\/doi.org\/10.1515\/cclm-2020-0502.","journal-title":"Clin Chem Lab Med (CCLM)."},{"key":"891_CR40","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637\u201345.","journal-title":"Lancet."},{"key":"891_CR41","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"key":"891_CR42","doi-asserted-by":"publisher","first-page":"107602962094539","DOI":"10.1177\/1076029620945398","volume":"26","author":"SA Berkman","year":"2020","unstructured":"Berkman SA, Tapson VF. Methodological issues and controversies in COVID-19 coagulopathy: a tale of two storms. Clin Appl Thromb Hemost. 2020;26:1076029620945398. https:\/\/doi.org\/10.1177\/1076029620945398.","journal-title":"Clin Appl Thromb Hemost."},{"key":"891_CR43","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/jmv.25964","volume":"92","author":"R Alattar","year":"2020","unstructured":"Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020;92:2042\u20139.","journal-title":"J Med Virol."},{"key":"891_CR44","unstructured":"U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA authorizes drug for treatment of COVID-19 [Internet]. Washington, D.C.: FDA; 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19"},{"key":"891_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2020","unstructured":"Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New Engl J Med. 2020;384:20\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2030340.","journal-title":"New Engl J Med."},{"key":"891_CR46","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Br\u00e4u N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New Engl J Med. 2021;384:1503\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2028700.","journal-title":"New Engl J Med."},{"key":"891_CR47","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","volume":"47","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med. 2021;47:1258\u201370. https:\/\/doi.org\/10.1007\/s00134-021-06507-x.","journal-title":"Intensive Care Med."},{"key":"891_CR48","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00134-021-06540-w","volume":"47","author":"KC Tatham","year":"2021","unstructured":"Tatham KC, Shankar-Hari M, Arabi YM. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19? Intensive Care Med. 2021;47:1315\u20138.","journal-title":"Intensive Care Med."},{"key":"891_CR49","doi-asserted-by":"publisher","first-page":"109975","DOI":"10.1016\/j.mehy.2020.109975","volume":"144","author":"AAR Mohamed-Hussein","year":"2020","unstructured":"Mohamed-Hussein AAR, Aly KME, Ibrahim M-EAA. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med Hypotheses. 2020;144:109975.","journal-title":"Med Hypotheses."},{"key":"891_CR50","unstructured":"U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of REGEN-COV (casirivimab and imdevimab) [Internet]. Washington, D.C.: FDA; 2021. Available from: https:\/\/www.fda.gov\/media\/145611\/download"},{"key":"891_CR51","unstructured":"U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of bamlanivimab and etesevimab [Internet]. Washington, D.C.: FDA; 2021. Available from: https:\/\/www.fda.gov\/media\/145802\/download"},{"key":"891_CR52","unstructured":"U.S. Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers Emergency Use Authorization (EUA) of sotrovimab [Internet]. Washington, D.C.: FDA; 2021. Available from: https:\/\/www.fda.gov\/media\/149534\/download"},{"key":"891_CR53","doi-asserted-by":"publisher","first-page":"Cd013825","DOI":"10.1002\/14651858.CD013825.pub2\/epdf\/full","volume":"9","author":"N Kreuzberger","year":"2021","unstructured":"Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021;9:Cd013825. https:\/\/doi.org\/10.1002\/14651858.CD013825.pub2\/epdf\/full.","journal-title":"Cochrane Database Syst Rev"},{"key":"891_CR54","unstructured":"CinicalTrials.gov. COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay (NCT04425629) [Internet]. Washington, D.C.: U.S. National Library of Medicine; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04452318?term=NCT04425629&draw=2&rank=2"},{"key":"891_CR55","unstructured":"Ferner RE, Aronson JK. (2020) Monoclonal antibodies directed against SARS-CoV-2: synthetic neutralizing antibodies, the REGN-COV2 antibody cocktail [Internet]. University of Oxford, U.K.: The Centre for Evidence-Based Medicine. Available from: https:\/\/www.cebm.net\/covid-19\/monoclonal-antibodies-directed-against-sars-cov-2-synthetic-neutralizing-antibodies-the-regn-cov2-antibody-cocktail\/"},{"key":"891_CR56","unstructured":"ClinicalTrials.gov. A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in participants with mild to moderate COVID-19 illness (BLAZE-1) (NCT04427501). Washington, D.C.: U.S. National Library of Medicine; 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04427501?term=NCT04427501&draw=2&rank=1"},{"key":"891_CR57","unstructured":"ClinicalTrials.gov (2021) A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in preventing SARS-CoV-2 infection and COVID-19 in Nursing home residents and Staff (BLAZE-2) (NCT04497987) [Internet]. Washington, D.C.: U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497987?term=NCT04497987&draw=2&rank=1"},{"key":"891_CR58","unstructured":"ClinicalTrials.gov (2021) A study of immune system proteins in participants with mild to moderate COVID-19 illness (BLAZE-4) (NCT04634409) [Internet]. Washington, D.C.: U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04634409?term=NCT04634409&draw=2&rank=1"},{"key":"891_CR59","unstructured":"ClinicalTrials.gov (2021) Intramuscular VIR-7831 (Sotrovimab) for Mild\/Moderate COVID-19 (NCT04913675) [Internet]. Washington, D.C.: U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04913675"},{"key":"891_CR60","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. New England J Med. 2021;385:1941\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2107934.","journal-title":"New England J Med"},{"key":"891_CR61","unstructured":"U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab [Internet]. Washington, D.C.: FDA; 2021. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab"},{"key":"891_CR62","unstructured":"U.S. Food and Drug Administration (FDA) (2022) Coronavirus (COVID-19) Update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant [Internet]. Washington, D.C.: FDA. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron"},{"key":"891_CR63","unstructured":"U.S. Food and Drug Administration (FDA) (2022) Coronavirus (COVID-19) Update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against omicron variant [Internet]. Washington, D.C.: FDA. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains"},{"key":"891_CR64","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41577-020-0365-7","volume":"20","author":"J Abraham","year":"2020","unstructured":"Abraham J. Passive antibody therapy in COVID-19. Nat Rev Immunol. 2020;20:401\u20133. https:\/\/doi.org\/10.1038\/s41577-020-0365-7.","journal-title":"Nat Rev Immunol."},{"key":"891_CR65","unstructured":"U.S. Food and Drug Administration (FDA) (2021) Fact sheet for Healthcare providers: emergency use authorization for EVUSHELDTM (tixagevimab co-packaged with cilgavimab) [Internet]. Washington, D.C.: FDA. Available from: https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/6d1d5fea-2532-46e9-a1d4-1504f6dd41b2\/6d1d5fea-2532-46e9-a1d4-1504f6dd41b2_viewable_rendition__v.pdf"},{"key":"891_CR66","unstructured":"U.S. Food and Drug Administration (FDA) (2021) Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals [Internet]. Washington, D.C.: FDA. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure"},{"key":"891_CR67","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813\u201326.","journal-title":"N Engl J Med"},{"key":"891_CR68","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:396.","journal-title":"Sci Transl Med."},{"key":"891_CR69","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269\u201371.","journal-title":"Cell Res."},{"key":"891_CR70","unstructured":"Gilead (2021) VEKLURY remdesivir [Internet]. Foster City, CA: Gilead Sciences, Inc. Available from: https:\/\/www.vekluryhcp.com\/?gclid=EAIaIQobChMIytGvhNHm9AIVeAaICR0QuwmYEAAYASAAEgJiUfD_BwE&gclsrc=aw.ds"},{"key":"891_CR71","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger F, Stiller C, Schmitzov\u00e1 J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:740\u20136. https:\/\/doi.org\/10.1038\/s41594-021-00651-0.","journal-title":"Nat Struct Mol Biol."},{"key":"891_CR72","unstructured":"Merck (2021) Merck and Ridgeback biotherapeutics provide update on results from MOVe-OUT study of Molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19 [Internet]. Kenilworth, NJ: Merck, Sharp, and Dohme, Corp. Available from: https:\/\/www.merck.com\/news\/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19\/"},{"key":"891_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03667-0","author":"M Kozlov","year":"2021","unstructured":"Kozlov M. Merck\u2019s COVID pill loses its lustre: what that means for the pandemic. Nature. 2021. https:\/\/doi.org\/10.1038\/d41586-021-03667-0.","journal-title":"Nature"},{"key":"891_CR74","unstructured":"U.S. Food and Drug Administration (FDA). (2021) Coronavirus (COVID-19) Update: FDA authorizes additional oral antiviral for treatment of COVID-19 in Certain Adults [Internet]. Washington, D.C.: U.S. Food and Drug Administration (FDA). Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain"},{"key":"891_CR75","unstructured":"Pfizer (2021) Pfizer announces additional Phase 2\/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death [Internet]. New York, New York: Pfizer, Inc. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-additional-phase-23-study-results"},{"key":"891_CR76","unstructured":"U.S. Food and Drug Administration (FDA) (2021) Coronavirus (COVID-19) Update: FDA authorizes first oral antiviral for treatment of COVID-19 [Internet]. Washington, D.C.: U.S. Food and Drug Administration (FDA). Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-022-00891-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-022-00891-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T14:21:14Z","timestamp":1687357274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-022-00891-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s10238-022-00891-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}